🔥 Saturday 21 March 2026 Sat, 21 Mar 2026

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

Payments and lending names wore the biggest swings as investors reacted to a large placement, a takeover repricing, and a governance brawl. Deal terms, disclosure quality, and access to funding mattered more than “big picture” talk this week.

A brutal sell-off in a few small caps did most of the damage this week, even as project funding and resource upgrades kept rolling in. Lithium, rare earths and tungsten news stayed constructive, but traders punished anything that looked like delays, dilution or weaker prices.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

Leadership changes and insider selling hit small-cap tech hard, while deal-driven updates and AI order wins kept buyers interested. The week’s biggest moves came from CEO exits, option exercises, and a handful of “special situation” announcements that traders tried to price in fast.